Motley Fool Wealth Management LLC Has $20.55 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Motley Fool Wealth Management LLC lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.6% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,217 shares of the medical research company’s stock after selling 1,967 shares during the period. Thermo Fisher Scientific comprises about 1.0% of Motley Fool Wealth Management LLC’s portfolio, making the stock its 28th biggest holding. Motley Fool Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $20,548,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of TMO. CWM LLC increased its holdings in Thermo Fisher Scientific by 9.5% in the 2nd quarter. CWM LLC now owns 18,358 shares of the medical research company’s stock worth $10,152,000 after purchasing an additional 1,590 shares in the last quarter. Howard Capital Management Group LLC increased its holdings in Thermo Fisher Scientific by 1.2% in the 2nd quarter. Howard Capital Management Group LLC now owns 54,289 shares of the medical research company’s stock worth $30,022,000 after purchasing an additional 632 shares in the last quarter. NBC Securities Inc. increased its holdings in Thermo Fisher Scientific by 27.3% in the 2nd quarter. NBC Securities Inc. now owns 2,389 shares of the medical research company’s stock worth $1,321,000 after purchasing an additional 513 shares in the last quarter. Valeo Financial Advisors LLC increased its holdings in Thermo Fisher Scientific by 2.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 4,150 shares of the medical research company’s stock worth $2,295,000 after purchasing an additional 111 shares in the last quarter. Finally, Csenge Advisory Group grew its position in shares of Thermo Fisher Scientific by 5.5% in the 2nd quarter. Csenge Advisory Group now owns 3,740 shares of the medical research company’s stock valued at $2,068,000 after buying an additional 194 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,150 shares of company stock valued at $20,651,865. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $534.42 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $487.06 and a one year high of $627.88. The business has a fifty day moving average price of $563.17 and a 200-day moving average price of $576.79. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The firm has a market capitalization of $204.42 billion, a P/E ratio of 33.51, a PEG ratio of 3.56 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same period last year, the company earned $5.69 earnings per share. The business’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current year.

Thermo Fisher Scientific announced that its board has authorized a share buyback plan on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TMO shares. Bank of America upped their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Redburn Atlantic began coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Stephens began coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective for the company. Finally, Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.